These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 22959093

  • 1. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).
    Sheridan DA, Neely RD, Bassendine MF.
    Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):10-6. PubMed ID: 22959093
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM.
    Adv Pharmacol; 2013 Feb; 67():169-215. PubMed ID: 23886001
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis C virus therapy update 2013.
    Casey LC, Lee WM.
    Curr Opin Gastroenterol; 2013 May; 29(3):243-9. PubMed ID: 23563981
    [Abstract] [Full Text] [Related]

  • 4. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
    Pol S, Corouge M, Mallet V, Sogni P.
    Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
    [Abstract] [Full Text] [Related]

  • 5. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z, Israeli Association for the Study of the Liver.
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [Abstract] [Full Text] [Related]

  • 6. [Antiviral treatment of chronic hepatitis C].
    Berger A.
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [Abstract] [Full Text] [Related]

  • 7. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ, Matthews GV, Rockstroh J.
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [Abstract] [Full Text] [Related]

  • 8. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.
    Chevaliez S.
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S46-51. PubMed ID: 22248694
    [Abstract] [Full Text] [Related]

  • 9. [Direct antiviral treatment strategies in chronic hepatitis C].
    Neumann-Haefelin C, Blum HE, Thimme R.
    Dtsch Med Wochenschr; 2012 Jun; 137(25-26):1360-5. PubMed ID: 22653493
    [Abstract] [Full Text] [Related]

  • 10. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C, Jesudian A, Zeuzem S, Jacobson I.
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [Abstract] [Full Text] [Related]

  • 11. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML, Dieterich DT.
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [Abstract] [Full Text] [Related]

  • 12. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z.
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [Abstract] [Full Text] [Related]

  • 13. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C.
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [Abstract] [Full Text] [Related]

  • 14. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
    Rodríguez-Torres M.
    Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
    [Abstract] [Full Text] [Related]

  • 15. Chronic hepatitis C: treatments of the future.
    Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P.
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S84-95. PubMed ID: 22248700
    [Abstract] [Full Text] [Related]

  • 16. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
    Shah N, Pierce T, Kowdley KV.
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
    Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E.
    World J Gastroenterol; 2015 Oct 14; 21(38):10749-59. PubMed ID: 26478667
    [Abstract] [Full Text] [Related]

  • 18. [Boceprevir: new possibilities for antiviral treatment of chronic hepatitis C].
    Nikitin IG, Baĭkova IE, Gogova LM, Volynkina VM, Kisliakov VA.
    Ter Arkh; 2013 Oct 14; 85(2):76-84. PubMed ID: 23653945
    [Abstract] [Full Text] [Related]

  • 19. The race for interferon-free HCV therapies: a snapshot by the spring of 2012.
    De Clercq E.
    Rev Med Virol; 2012 Nov 14; 22(6):392-411. PubMed ID: 22936636
    [Abstract] [Full Text] [Related]

  • 20. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
    Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.
    Z Gastroenterol; 2012 Jan 14; 50(1):57-72. PubMed ID: 22222799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.